Arimidex
FDA Approves Kadcyla for Late-stage Breast Cancer »
"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
Read the FDA Approves Kadcyla for Late-stage Breast Cancer article »
Arimidex
INDICATIONS
Adjuvant Treatment
ARIMIDEX (anastrozole) is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
First-Line Treatment
ARIMIDEX (anastrozole) is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
Second-Line Treatment
ARIMIDEX (anastrozole) is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX (anastrozole) .
DOSAGE AND ADMINISTRATION
Recommended Dose
The dose of ARIMIDEX (anastrozole) is one 1 mg tablet taken once a day. For patients with advanced breast cancer, ARIMIDEX (anastrozole) should be continued until tumor progression. ARIMIDEX (anastrozole) can be taken with or without food.
For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown. In the ATAC trial ARIMIDEX (anastrozole) was administered for five years. [see Clinical Studies]
No dosage adjustment is necessary for patients with renal impairment or for elderly patients. [see Use in Specific Populations]
Patients with Hepatic Impairment
No changes in dose are recommended for patients with mild-to-moderate hepatic impairment. ARIMIDEX (anastrozole) has not been studied in patients with severe hepatic impairment. [see Use in Specific Populations]
HOW SUPPLIED
Dosage Forms And Strengths
The tablets are white, biconvex, film-coated containing 1 mg of anastrozole. The tablets are impressed on one side with a logo consisting of a letter "A" (upper case) with an arrowhead attached to the foot of the extended right leg of the "A" and on the reverse with the tablet strength marking "Adx 1".
These tablets are supplied in bottles of 30 tablets (NDC 0310-0201-30) and in a 30-count blister package (NDC 0310-0201-37).
Storage
Store at controlled room temperature, 20-25°C (68-77°F) [see USP].
AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. Rev 04-30-09
Last reviewed on RxList: 12/2/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Arimidex Information
Arimidex - User Reviews
Arimidex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Arimidex sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Breast Cancer
Find support and advances in treatment.
Updated & New
